![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions.
Lead Product(s): VMT01
Therapeutic Area: Oncology Product Name: VMT01
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Viewpoint Molecular Targeting
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 06, 2023